Treatment for urticaria in Scotland

The Scottish Medicines Consortium has recommended the use of omalizumab for the treatment of patients with chronic spontaneous urticaria

The consortium recommends omalizumab as an add-on therapy for chronic spontaneous urticaria in adults and adolescents aged over 12 years whose condition has shown an inadequate response to combination therapy with H1 antihistamines, leukotriene receptor antagonists and H2 antihistamines.
During three placebo-controlled trials (ASTERIA I, ASTERIA II and GLACIAL) involving 1,000 patients not responding to H1 antihistamine treatment, omalizumab 300mg was shown to significantly improve itch and hives. Quality of life was also significantly improved for patients treated with omalizumab across the phase III study programme.
Professor David Burden, consultant dermatologist at the Western Infirmary, Glasgow, said: 'Chronic spontaneous urticaria can be a very distressing condition, which has a huge impact on patients' physical and psychological wellbeing. For many years, treatment options for these patients have been severely limited. Today's recommendation from the Scottish Medicines Consortium is very welcome and provides people living with chronic spontaneous urticaria and their healthcare professionals an important new treatment option. This will make a huge difference to the lives of many patients.'
Scottish Medicines Consortium. omalizumab 150mg solution for injection (Xolair) SMC No (1017/14). December 2014

Want news like this straight to your inbox?
Sign up for our bulletins

Read these next

Low vitamin D in photosensitive patients

Low vitamin D in photosensitive patients

According to a recent study, photosensitive patients...

Psychological care: Quality of life assessment in skin disease

Psychological care: Quality of life assessment in skin disease

Patients should be assessed for the impact on their...

Pictorial case studies: Cutaneous drug reactions

Pictorial case studies: Cutaneous drug reactions

A systematic approach is required in diagnosing adverse...

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases